**EXPERTS DISCUSS THE FUTURE OF AI IN BIOTECH AT BIO-EUROPE 2023**
Artificial intelligence (AI) in drug discovery and development has been rapidly growing, but experts at the BIO-Europe 2023 conference say there are still obstacles to overcome. Najat Khan from Janssen Research & Development highlighted the “lack of trust and scepticism due to a lack of understanding” as a major challenge in AI-focused biotechs. She emphasized that proper communication and understanding of the deployment of new technologies are crucial.
CEO of Owkin, Thomas Clozel, echoed the sentiment, saying that communication of vision to investors is one of the current struggles. He emphasized the need for both tech and pharma investors to fully understand the value of the work that AI startups and scale-ups do. Despite these challenges, both experts remained optimistic about the prospects of AI in pharma, especially in drug development.
Clozel emphasized the importance of wider access to data in a “federated manner”, as data is crucial in the continued improvement of the field. Khan and Clozel highlighted the potential of AI in bringing more causality in drug development, a deeper understanding of the drug, and allowing for a deeper understanding of the biological underpinnings of disease.
What do you think about the future of AI in biotech? Are you excited about the possibilities, or do you see potential challenges ahead? Let us know in the comments below!
IntelliPrompt curated this article: Read the full story at the original source by clicking here